2. Academic Validation
  3. Long-term administration of oral low-dose topoisomerase II inhibitors, MST-16 and VP-16, for refractory or relapsed non-Hodgkin's lymphoma

Long-term administration of oral low-dose topoisomerase II inhibitors, MST-16 and VP-16, for refractory or relapsed non-Hodgkin's lymphoma

  • Acta Haematol. 2000;104(2-3):128-30. doi: 10.1159/000039746.
T Okamoto 1,  Y Nishimura,  S Yamada,  S Yamada,  T Itoh,  A Mori,  K Saheki,  M Okada,  H Takatsuka,  H Wada,  A Tamura,  Y Fujimori,  E Kakishita
Affiliations

Affiliation

  • 1 Second Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan. tak-o@hyo-med.ac.jp
PMID: 11154989 DOI: 10.1159/000039746
Abstract

It is known that the Topoisomerase II inhibitors, MST-16 (sobuzoxane) and VP-16 (etoposide), are effective for the treatment of lymphoma. Five patients with refractory or relapsed non-Hodgkin's lymphoma (NHL) were treated with a combination of oral MST-16 and VP-16 over a long period. Two patients had severely refractory NHL. The remaining 3 patients could not be treated with intensive chemotherapy because of severe organ dysfunction or a poor hematopoietic reserve. All 5 are alive and well after MST-16 and VP-16 treatment. MST-16 and VP-16 are effective for NHL when intensive chemotherapy is ineffective or contraindicated.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z